Esomeprazole (MUPS preparation)

Esomeprazole (MUPS preparation) Uses, Dosage, Side Effects, Food Interaction and all others data.

Esomeprazole MUPS 20 Tablet: Each MUPS tablet contains 133.333 mg (15%w/w) of Esomeprazole enteric coated pellets equivalent to 20 mg Esomeprazole (as Esomeprazole Magnesium Trihydrate USP). Esomeprazole MUPS 40 Tablet: Each MUPS tablet contains 266.67 mg (15% w/w) of Esomeprazole enteric coated pellets equivalent to 40 mg Esomeprazole (as Esomeprazole Magnesium Trihydrate USP).

Esomeprazole (MUPS preparation)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Esomeprazole (MUPS preparation)
Generic	Esomeprazole (MUPS preparation)
Type
Therapeutic Class
Manufacturer
Available Country	Bangladesh
Last Updated:	September 24, 2024 at 5:38 am

Uses

Esomeprazole MUPS tablet is indicated in: Gastro-esophageal Reflux Disease (GERD). Risk reduction in NSAID associated gastric ulcer. H. pylori eradication (Triple therapy). Zollinger-Ellison syndrome and idiopathic hypersecretion.

Dosage

Esomeprazole (MUPS preparation) dosage

Erosive esophagitis- Adult (≥18 years): 40 mg once daily for 4 weeks. Children & adolescents (12-18 years): 40 mg once daily for 4 weeks. Maintenance of healing of erosive esophagitis- Adult (≥18 years): 20 mg once daily. Children & adolescents (12-18 years): 20 mg once daily. Risk reduction in NSAID associated gastric ulcer- Adult (≥18 years): 20 mg once daily for 4-8 weeks. H. pylori eradication (Esomeprazole MUPS tablet with 1000 mg Amoxicillin and 500 mg Clarithromycin)- Adult (≥18 years): 20 mg twice daily for 7 days. Children & adolescents (12-18 years): 20 mg twice daily for 7 days. Zollinger-Ellison syndrome and idiopathic hypersecretion- Adult (≥18 years): 40-80 mg twice daily. Children 1-11 years: Erosive esophagitis: Weight <20 kg: 10 mg once daily for 8 weeks. Weight ≥20 kg: 10 mg or 20 mg once daily for 8 weeks Maintenance of healing of erosive esophagitis: 10 mg once daily Children below the age of 1 year: Esomeprazole MUPS tablet is not approved for use in children younger than 1 year. Esomeprazole MUPS tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed. If required, the tablets can also be dispersed in half a glass of non-carbonated water (mineral water is not suitable). No other liquids should be used. Stir until the tablets disintegrate and drink the liquid with the pellets immediately or within 30 minutes. Rinse the glass with half a glass of water and drink. The pellets must not be chewed or crushed.

Side Effects

The most frequently occurring adverse events reported with Esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. There are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment.

Precaution

Esomeprazole should be used carefully if the patient has severe liver dysfunction and severe renal impairment. Taking a proton pump inhibitor like Esomeprazole may slightly increase the risk of hip, wrist and spine fracture, particularly when it is taken over a period of more than one year.

Interaction

Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4. In vitro and in vivo studies have shown that Esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4. No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected. Drug interaction studies have shown that Esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin. Esomeprazole may potentially interfere with CYP2C19, the major Esomeprazole metabolizing enzyme. Co-administration of Esomeprazole 30 mg anddiazepam, a CYP2C19 substrate has resulted in a 45% decrease in clearance of diazepam. Increased plasma levels of diazepam have been observed 12 hours after dosing and onwards. Esomeprazole inhibits gastric acid secretion. Therefore, Esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin). Co-administration of oral contraceptives, diazepam, phenytoin, or quinidine do not seem to change the pharmacokinetic profile of Esomeprazole. Combination Therapy with Clarithromycin: Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.